Clinical Report: CD19 CAR T Therapy Tested in Refractory Rheumatoid Arthritis

Overview

A single infusion of CD19 CAR T cells reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis. Follow-up periods ranged from 36 to 52 weeks.

Background

Rheumatoid arthritis (RA) is a chronic inflammatory disorder that can lead to significant morbidity and disability. Traditional treatments often fail in patients with refractory disease.

Data Highlights

Key Findings

• All six participants experienced a reduction in disease activity scores.
• Three participants maintained remission without disease-modifying drugs or glucocorticoids.
• Grade 1 or 2 cytokine release syndrome occurred in all participants but resolved after treatment.
• Four participants became seronegative for rheumatoid arthritis-associated autoantibodies.
• No severe adverse events were reported during the study.

Clinical Implications

Further research is needed to evaluate the long-term safety and efficacy of CD19 CAR T cell therapy in patients with refractory rheumatoid arthritis.

Conclusion

This initial trial indicates that CD19 CAR T therapy may reduce disease activity in severe rheumatoid arthritis.

Related Resources & Content

1. MDSpire News, 2025 -- CD19 CAR T-Cell Therapy in Patients With Autoimmune Disease
2. the asco post, 2025 -- CD19 CAR T-Cell Therapy May Be Effective in Treating Resistant Ulcerative Colitis
3. the asco post, 2025 -- Enhanced CAR T-Cell Therapy for Lymphoma After Previous Failure on CAR T-Cell Therapy
4. Recommendations Management | EULAR, 2026 -- EULAR Recommendations Management
5. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial, Nature Medicine, 2026
6. the asco post — Novel CAR T-Cell Therapy Under Study in Relapsed or Refractory Non-Hodgkin Lymphoma
7. Recommendations Management | EULAR
8. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial | Nature Medicine
9. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial | Nature Medicine